Apigenin: what the evidence says about sleep, anxiety, and the NAD+ longevity claim

Apigenin is a flavonoid found in chamomile, parsley, and celery that has been popular for two very different reasons. For years it was a quiet ingredient in bedtime teas, sold on the idea that it calms the nervous system. More recently it has been repackaged as a longevity molecule — a way to protect the body's NAD⁺ supply. Both stories have a real mechanistic basis. Both also lean heavily on preclinical work and on chamomile trials rather than on studies of isolated apigenin in people. Here is what actually holds up.

Sleep and anxiety: a real mechanism, mostly tested as chamomile

The calming story starts with a genuine finding. In classic pharmacology work, apigenin was identified as a component of Matricaria recutita (chamomile) flowers that acts as a central benzodiazepine receptor ligand with anxiolytic effects in animals — the same receptor family that sedatives like diazepam target, part of the GABA-A system.^[1] That gives the “apigenin relaxes you” claim a plausible molecular handle rather than pure marketing.

The human evidence, though, is almost entirely about chamomile, not isolated apigenin. A randomized, double-blind, placebo-controlled trial found that a standardized chamomile extract produced a modest reduction in symptoms of generalized anxiety disorder,^[2] and a longer-term randomized trial reported that chamomile was well tolerated and may reduce anxiety symptoms over months of use, though it did not significantly prevent relapse versus placebo.^[3] On sleep, a small placebo-controlled pilot in people with chronic insomnia found chamomile extract produced only modest, non-significant improvements in sleep measures.^[4] This is the crux: chamomile contains apigenin along with dozens of other compounds, so a chamomile result cannot be cleanly attributed to apigenin the isolated supplement. If sleep is your actual goal, the better-supported levers are behavioral and covered in our guide to how to increase deep sleep.

The longevity angle: CD38, NAD⁺, and a mechanism that stops at animals

The newer pitch is that apigenin preserves NAD⁺, the coenzyme central to energy metabolism and DNA-repair signaling that tends to fall with age. The basis is a specific enzyme: apigenin was shown to be an inhibitor of CD38, an NADase that consumes NAD⁺. In that study, inhibiting CD38 with apigenin raised intracellular NAD⁺ and improved metabolic parameters in mouse models of diet-induced obesity.^[5] So the logic — block the enzyme that burns NAD⁺, and you keep more of it — is coherent and interesting.

But it is cell and animal evidence. There is no human trial showing that oral apigenin raises NAD⁺ levels, slows aging, or extends healthspan in people. That is the same gap that dogs the supplement side of the field: the direct NAD⁺-raising strategy of the NAD⁺ precursors NR and NMN reliably lifts blood NAD⁺ markers in humans yet still has not delivered clear anti-aging outcomes, and apigenin is a step further back — it hasn't even been shown to move the NAD⁺ needle in humans. Apigenin also sits in the same broad flavonoid family as quercetin and fisetin, both of which share the pattern of striking preclinical mechanisms and thin confirmatory human data.

Antioxidant and anti-inflammatory breadth — in the lab

Reviews of apigenin catalog a wide range of antioxidant, anti-inflammatory, and anticancer activity across in-vitro and animal models, along with an unusually favorable safety and tolerability profile.^[6]This breadth is real and is part of why apigenin keeps resurfacing in longevity discussions. It is also exactly the kind of “does everything in a dish” profile that many dietary flavonoids share, and that rarely translates cleanly to humans — in part because apigenin's oral bioavailability is low. The volume of preclinical papers should not be mistaken for a volume of human proof.

The honest bottom line

Apigenin is popular, mechanistically interesting, and well tolerated — and its human evidence is mostly indirect. What is genuinely supported: a plausible GABA-A/benzodiazepine mechanism, and modest human trial data for chamomile in anxiety and, more weakly, sleep. What is not supported: that isolated apigenin reliably improves human sleep, that it raises NAD⁺ or slows aging in people, or that its broad antioxidant effects have been confirmed in isolated-apigenin human RCTs. The CD38-to-NAD⁺ longevity narrative is a hypothesis built on animal and cell data, not a human result. If you find it calming or enjoy it as chamomile, the safety bar is low. Just hold the longevity claims lightly: this is a molecule where the mechanisms have run well ahead of the human evidence. None of this is medical advice.